132260-10-7

Upstream product

• 383-63-1 ethyl trifluoroacetate, 
• 132260-09-4 3,2',6'-tris-N-(tert-butoxycarbonyl)kanamycin B 
• 4696-76-8 kananmycin B 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 132260-18-5 1-C-(hydroxymethyl)kanamycin B 
• 132260-18-5 C₁₉H₃₉N₅O₁₁ 
• 132260-23-2 1-C-(hydroxymethyl)-6''-O-<(2,4,6-triisopropylphenyl)sulfonyl>-1,3,2',6',3''-penta-N-BOC-kanamycin B 
• 132260-22-1 C₅₄H₉₁N₅O₂₃S 
• 132260-21-0 C₅₃H₈₉N₅O₂₂S 
• 132260-20-9 C₅₃H₉₁N₅O₂₀S 
• 132260-25-4 1-C-(hydroxymethyl)-6''-deoxy-6''-azido-1,3,2',6',3''-pentakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-26-5 1-C-(hydroxymethyl)-6''-deoxy-6''-acetamido-1,3,2',6',3''-pentakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-13-0 1-N-<(benzyloxy)carbonyl>-3,2',6',3''-tetrakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-24-3 1-C-(hydroxymethyl)-6''-deoxy-6''-chloro-1,3,2',6',3''-pentakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-27-6 C₄₄H₈₀N₆O₂₀ 
• 132260-16-3 1-C-(hydroxymethyl)-1-deamino-1-nitro-3,2',6',3''-tetrakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-15-2 1-deamino-1-nitro-3,2',6',3''-tetrakis-N-(tert-butoxycarbonyl)kanamycin B 
• 132260-12-9 1-N-<(benzyloxy)carbonyl>-3,2',6'-tris-N-(tert-butoxycarbonyl)kanamycin B 

Relevant academic research and scientific papers

NOVEL ANTIBACTERIAL 3"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS

The present invention relates to novel aminoglycoside compounds having antimicrobial properties and being suitable, for example, as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The invention further relates to compounds for use in the treatment of diseases whose treatment is made otherwise difficult due to antibiotic-class-related bacterial resistance and provides novel therapeutic agents suitable for use in the treatment of multidrug-resistant (MDR) infections.

New derivatives of kanamycin B obtained by combined modifications in positions 1 and 6″. Synthesis, microbiological properties, and in vitro and computer-aided toxicological evaluation

Substitution of the C-1 atom in the 2-deoxystreptamine moiety of gentamicin C2, a broad-spectrum aminoglycoside antibiotic, by an axial hydroxymethyl group has been reported to confer protection against most clinically important bacterial enzym